Table 2.

Clinical trials on engineered TCR-T cells against AML

NCT Number	Target	HLA Allele	Conditioning regimen	TCR Transduced Method	Phase	Participants	Status/results
NCT01640301	WT1	HLA-A2	Cyclophosphamide; Fludarabine	Lentiviral vector	I/II	12	Terminated / RFS* 100% at a median of 44 months after infusion
NCT05066165	WT1	HLA-A*02:01	Cyclophosphamide; Fludarabine	CRISPR/Cas9	I/II	54	Active, not recruiting
NCT01621724	WT1	HLA-A*02:01	N.A	Retroviral vector	I/II	7	Completed
NCT03326921	HA1	HLA-A*02:01	Fludarabine	N.A	I	24	Recruiting
NCT02550535	WT1	HLA-A*02:01	Fludarabine; Methylprednisolone	N.A	I/II	3	Completed
NCT02770820	WT1	HLA-A*02:01	N.A	N.A	I/II	9	Terminated
NCT02743611	PRAME	HLA-A2	N.A	N.A	I/II	28	Unknown
NCT03503968	PRAME	HLA-A*02:01	N.A	N.A	I/II	92	Recruiting

^*RFS: Relapse-free survival